CGC-11047 + cisplatin

CGC-11047 is a polyamine analog developed as an apoptosis stimulant for cancer therapy. It acts by inhibiting polyamine biosynthetic enzymes, inducing catabolic enzymes such as spermidine/spermine N(1)-acetyltransferase (SSAT) and spermine oxidase (SMO), leading to increased reactive oxygen species and tumor cell death. The drug exploits the dysregulation of polyamine metabolism in cancer cells, entering rapidly dividing cells via a selective transport system and interfering with their growth[3][4]. Cisplatin is a platinum-based chemotherapy agent that functions primarily as an alkylating agent, cross-linking DNA strands to prevent replication and induce cell death. It is widely used in the treatment of various cancers including sarcomas, carcinomas, lymphomas, and germ cell tumors[7]. The combination of CGC-11047 with cisplatin has been investigated in preclinical models (notably lung cancer), where CGC-11047 potentiated the antitumor effect of cisplatin[4]. Clinical trials have evaluated this combination to determine safety and maximum tolerated dose in advanced solid tumors[5].

Brand names

Platinol

Other names

cis-diamminedichloroplatinum(II)